4-(hydroxymethyl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside | 912281-46-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(hydroxymethyl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside
• 英文别名: (2R,3R,4S,5S,6R)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate；[(2R,3R,4S,5S,6R)-3,4,5-triacetyloxy-6-[4-(hydroxymethyl)phenoxy]oxan-2-yl]methyl acetate
• CAS: 912281-46-0
• 化学式: C₂₁H₂₆O₁₁
• 分子量: 454.431
• InChiKey: HGUDVDQXCUHOED-MJCUULBUSA-N

物化性质

• 沸点：
  551.4±50.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  32
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  4-(hydroxymethyl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 在 吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 4-[4-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)-benzyloxycarbonyl]amino-5-(methylsulfanyl)cyclopentane-1,2,3-triol
  参考文献：
  名称：

  反馈前药对糖苷酶的选择性抑制。

  摘要：

  DOI：

  10.1002/anie.200600808
• 作为产物：
  描述：

  4-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)-benzaldehyde 在 sodium tetrahydroborate 、 silica gel 作用下， 以 氯仿 、 异丙醇 为溶剂， 以82%的产率得到4-(hydroxymethyl)phenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside
  参考文献：
  名称：

  反馈前药对糖苷酶的选择性抑制。

  摘要：

  DOI：

  10.1002/anie.200600808

文献信息

• [EN] IMMUNOSTIMULATORY COMPOUNDS AND CONJUGATES<br/>[FR] COMPOSÉS ET CONJUGUÉS IMMUNOSTIMULATEURS
  申请人：SEAGEN INC

  公开号：WO2022170002A1

  公开（公告）日：2022-08-11

  The present disclosure provides,inter alia, antibody drug conjugates that are useful in treating various diseases such as cancer. The antibody drug conjugates can be configured to elicit tumor site-specific responses, including tumor microenvironment immunostimulation, while limiting off-target and systemic effects. In certain embodiments disclosed herein, the antibody drug conjugates are configured to release payloads following internalization by immune, cancer, or tumor associated cells.

  本公开说明提供了抗体药物结合物，可用于治疗各种疾病，例如癌症。抗体药物结合物可配置为引发肿瘤位点特异性反应，包括肿瘤微环境免疫刺激，同时限制非靶向和系统效应。在本文所披露的某些实施例中，抗体药物结合物被配置为在免疫、癌症或肿瘤相关细胞内部化后释放有效药物。
• WO2007/98033
  申请人：——

  公开号：——

  公开（公告）日：——
• Glycosidase-activated H2S donorsto enhance chemotherapy efficacy
  作者：Zizhen Ye、Jixiang Li、Jiarui Shi、Yuguang Song、Yangping Liu、Jingli Hou

  DOI：10.1016/j.bmcl.2024.129644

  日期：2024.3
• FEEDBACK PRODRUG
  申请人：BOONS Geert-Jan

  公开号：US20120058960A1

  公开（公告）日：2012-03-08

  Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.
• ELECTROCHEMICAL METHODS AND COMPOUNDS FOR THE DETECTION OF ENZYMES
  申请人：GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION

  公开号：US20170102349A1

  公开（公告）日：2017-04-13

  Disclosed are compositions and methods for the electrochemical detection of enzymes, such as enzymes that are indicative of disease, disorders, or pathogens, such as viruses, bacteria, and fungi, or other disorders. These methods can be used in point-of-care diagnostic assays for the detection of disease, disorder, or pathogen (e.g., to identify the strain of pathogen infecting a patient in a healthcare setting). The electrochemical methods described herein can also be used to assess the susceptibility of a pathogen to an antipathogen drug. Also provided are probes suitable for use in conjunction with the methods described herein.